Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis

Inflammation

Volumn 38, Issue 6, 2015, Pages 2105-2115

  Zhang, Yun Fang ^a,b,c   Zou, Xun Liang ^a,d   WU, Jun ^a,b   Yu, Xue Qing ^a,b   Yang, Xiao ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

inflammation; NF B; peritonitis; peroxisome proliferator activated receptor (PPAR) ; rosiglitazone

Indexed keywords

CD40 ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PERITONEAL DIALYSIS FLUID; ROSIGLITAZONE; TRANSCRIPTION FACTOR RELA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; I KAPPA B; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI O111 B4; NF-KAPPAB INHIBITOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RELA PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIALYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOCHEMISTRY; INFLAMMATION; LEUKOCYTE COUNT; MALE; NONHUMAN; PERITONEAL DIALYSIS; PERITONITIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THICKNESS; ULTRAFILTRATION; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PERITONEUM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD40; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PERITONEUM; PERITONITIS; PHOSPHORYLATION; PPAR GAMMA; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84946482328     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0193-2     Document Type: Article

References (33)

1. Krediet, R.T. 2007. 30 years of peritoneal dialysis development: the past and the future. Peritoneal Dialysis International 27: S35–S41.
2. Gokal, R. 2002. Peritoneal dialysis in the 21st century: an analysis of current problems and future developments. Journal of the American Society of Nephrology 13: S104–S116.
3. Fan, X., R. Huang, J. Wang, H. Ye, Q. Guo, C. Yi, J. Lin, Q. Zhou, F. Shao, X. Yu, and X. Yang. 2014. Risk factors for the first episode of peritonitis in Southern Chinese continuous ambulatory peritoneal dialysis patients. PLoS ONE 9, e107485.
4. Szeto, C.C., and K.M. Chow. 2007. Gram-negative peritonitis—the Achilles heel of peritoneal dialysis? Peritoneal Dialysis International 27: S267–S271.
5. Feng, X., X. Yang, C. Yi, Q. Guo, H. Mao, Z. Jiang, Z. Li, D. Chen, Y. Cui, and X. Yu. 2014. Escherichia coli peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a South China dialysis center. Peritoneal Dialysis International 34: 308–16.
6. Devuyst, O., P.J. Margetts, and N. Topley. 2010. The pathophysiology of the peritoneal membrane. Journal of the American Society of Nephrology 21: 1077–1085.
7. Park, J.H., Y.G. Kim, M. Shaw, T.D. Kanneganti, Y. Fujimoto, K. Fukase, N. Inohara, and G. Núñez. 2007. Nod1/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells. Journal of Immunology 179: 514–521.
8. Laman, J.D., M. de Boer, and B.A. Hart. 1998. CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Developmental Immunology 6: 215–222.
9. Zhang, Y.F., X. Yang, Y.J. Zhang, Y.L. Sun, X.L. Zou, Q.Y. Kong, X.Q. Dong, X.Q. Ye, and X.Q. Yu. 2006. Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: its potential role in peritoneal cavity local defense. American Journal of Nephrology 26: 602–611.
10. Wu, J., X. Yang, Y.F. Zhang, S.F. Zhou, R. Zhang, X.Q. Dong, J.J. Fan, M. Liu, and X.Q. Yu. 2009. Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflammation Research 58: 473–482.
11. Forman, B.M., P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803–12.
12. Lehmann, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). Journal of Biological Chemistry 270: 12953–6.
13. Blanquart, C., O. Barbier, J.C. Fruchart, B. Staels, and C. Glineur. 2003. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. Journal of Steroid Biochemistry and Molecular Biology 85: 267–73.
14. 14-prostaglandin J2 ameliorates endotoxin-induced acute lung injury in rats. Chinese Medical Journal 127: 815–20.
15. Kim, J.C., Y.H. Lee, M.K. Yu, N.H. Lee, J.D. Park, G. Bhattarai, and H.K. Yi. 2012. Anti-inflammatory mechanism of PPAR γ on LPS-induced pulp cells: role of the ROS removal activity. Archives of Oral Biology 57: 392–400.
16. Nizamutdinova, I.T., Y.M. Kim, H.J. Kim, H.G. Seo, J.H. Lee, and K.C. Chang. 2009. Carbon monoxide (from CORM-2) inhibits high glucose-induced ICAM-1 expression via AMP-activated protein kinase and PPAR-gamma activations in endothelial cells. Atherosclerosis 207: 405–11.
17. Sauter, M., K. Kastenmüller, F. Belling, M. Wörnle, R. Ladurner, T. Mussack, and T. Sitter. 2012. Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cells. Mediators of Inflammation 2012: 217696.
18. Sandoval, P., J. Loureiro, G. González-Mateo, M.L. Pérez-Lozano, A. Maldonado-Rodríguez, J.A. Sánchez-Tomero, L. Mendoza, B. Santamaría, A. Ortiz, M. Ruíz-Ortega, R. Selgas, P. Martín, F. Sánchez-Madrid, A. Aguilera, and M. López-Cabrera. 2010. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Laboratory Investigation 90: 1517–32.
19. Sun, H., Y. Huang, X. Yu, Y. Li, J. Yang, R. Li, Y. Deng, and G. Zhao. 2008. Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. International Journal of Developmental Neuroscience 26: 505–15.
20. Zhang, Y.J., X. Yang, Q.Y. Kong, Y.F. Zhang, W.Y. Chen, X.Q. Dong, X.Y. Li, and X.Q. Yu. 2006. Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). American Journal of Nephrology 26: 356–62.
21. Kielian, T., M. McMahon, E.D. Bearden, A.C. Baldwin, P.D. Drew, and N. Esen. 2004. S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-delta12,14- prostaglandin J2 (15d-PGJ2). Journal of Neurochemistry 90: 1163–72.
22. Hontecillas, R., W.T. Horne, M. Climent, A.J. Guri, C. Evans, Y. Zhang, B.W. Sobral, and J. Bassaganya-Riera. 2011. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunology 4: 304–13.
23. Luo, Y., C. Liang, C. Xu, Q. Jia, D. Huang, L. Chen, K. Wang, Z. Wu, and J. Ge. 2004. Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. Journal of Cardiovascular Pharmacology 44: 381–5.
24. Wakino, S., U. Kintscher, Z. Liu, S. Kim, F. Yin, M. Ohba, T. Kuroki, A.H. Schonthal, W.A. Hsueh, and R.E. Law. 2001. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase C delta pathway in vascular smooth muscle cells. Journal of Biological Chemistry 276: 47650–47657.
25. Gosset, P., A.S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, J. Pestel, A.B. Tonnel, and F. Trottein. 2001. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology 31(10): 2857–65.
26. Hayden, M.S., and S. Ghosh. 2008. Shared principles in NF-κB signaling. Cell 132: 344–362.
27. Yamamoto, Y., and R.B. Gaynor. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends in Biochemical Sciences 29: 72–79.
28. Cruz, M.T., C.B. Duarte, M. Gonçalo, A.P. Carvalho, and M.C. Lopes. 2001. LPS induction of I kappa B-alpha degradation and iNOS expression in a skin dendritic cell line is prevented by the Janus kinase 2 inhibitor, tyrphostin b42. Nitric Oxide 5(1): 53–61.
29. Taggart, C.C., C.M. Greene, N.G. McElvaney, and S. O’Neill. 2002. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. Journal of Biological Chemistry 277(37): 33648–53.
30. Verma, I.M., J.K. Stevenson, E.M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes and Development 9(22): 2723–35.
31. Liu, Z.N., M. Zhao, Q. Zheng, H.Y. Zhao, W.J. Hou, and S.L. Bai. 2013. Inhibitory effects of rosiglitazone on paraquat-induced acute lung injury in rats. Acta Pharmacologica Sinica 34: 1317–24.
32. He, X., L. Feng, H. Meng, X. Wang, and S. Liu. 2012. Rosiglitazone protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity through inhibition of microglia activation. International Journal of Neuroscience 122: 532–40.
33. Leypoldt, J.K., C.D. Kemerath, and J.F. Gilson. 2007. Acute peritonitis in a C57BL/6 mouse model of peritoneal dialysis. Advances in Peritoneal Dialysis 23: 66–70.